Work

Molecular Characterization of Acquired Resistance to the BRAF Inhibitor Dabrafenib in a Patient with BRAF-Mutant Non–Small-Cell Lung Cancer

Year: 2013

Type: article

Source: Journal of Thoracic Oncology

DOI: 10.1097/jto.0b013e31828bb1b3

Authors: Charles M. Rudin, Kelvin Hong, Michael Streit

Institutions: Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, GlaxoSmithKline (United States)

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: GlaxoSmithKline, National Institutes of Health, National Cancer Institute

Awards: G1165598027, Lung Cancer Mutation Analysis

OpenAlex ID: W2006195227

FWCI: 11.27

Cites: 5

Cited by: 105

Related to: 10